Dr. Brenda Wong and her colleagues at Cincinnati Children’s Hospital healthcare center in Ohio are actively recruiting boys with Duchenne for their IGF-1 study: safety and Efficacy study of IGF-I in Duchenne Muscular Dystrophy.
The objective of this study is to ascertain whether IGF-I (insulin-like growth factor-I) therapy, also known as Increlex, improves or preserves muscle function in Duchenne Muscular Dystrophy (DMD). The investigators also want to discover if IGF-I can reduce glucocorticoid side effects along the lines of growth failure and insulin resistance.
Male with a diagnosis of DMD
Age 5 many years or older
Using daily glucocorticoid treatment (prednisone or deflazacort) for greater than 12 months
This study entails two groups. Participants inside the first group will receive IGF-I (Increlex) once daily by subcutaneous injection every single morning with breakfast for a duration of 6 months, plus they will also carry on to take their glucocorticoid. Participants inside the second group will only take their glucocorticoid.
This study requires spot at Cincinnati Children’s Hospital healthcare center in Cincinnati, Ohio. There are three study visits required more than a 6-month period. All study visits must come about at Cincinnati Children’s Hospital healthcare Center. There is funding available to help with travel to the study.